Live news related to ABIVAX stock (FR0012333284): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on ABIVAX mainly cover share price moves, earnings publications et M&A activity. The stock trades at €85,80 on Euronext Paris, down 3,76% at the last update. This page lists the articles published on ABIVAX stock to track the share price, company announcements and any item likely to influence market perception.
French biotech Abivax recovers in the trading session, climbing 8.16% to €90.80 and taking the lead in the SBF 120 index. The stock regains the top sp…
The French biotech continues its recovery from yesterday after the sharp drop following the phase 3 results of obefazimod. The stock leads the SBF 120…
The French biotech regains ground after a bleak session that saw its share price plummet by about 31%. The stock is attempting a technical stabilizati…
The French biotech faces a sharp setback the day after the phase 3 results of its flagship drug candidate in ulcerative colitis. The market heavily pe…
Abivax announced on Monday positive results from the phase 3 ABTECT maintenance trial evaluating obefazimod in active moderate to severe ulcerative co…
The French biotech continues its climb after several weeks of volatility around its quarterly earnings. The stock stands out again among the SBF 120 l…
The French biotech continues its upward trend during the session, following several days of turmoil around its quarterly earnings. The stock reached a…
The French biotech regains control during the session after several days of volatility below €118. The stock has crossed a closely monitored technical…
The French biotech experiences a turbulent session. After breaking through its technical resistance and setting a new intraday high, the stock returne…
Abivax confirms the sustained efficacy of its candidate obefazimod in ulcerative colitis with three-year data, showing 68% of patients in clinical rem…
